Shares of Aemetis Inc. (NASDAQ: AMTX) experienced a significant increase of 32.67% to reach $3.24 during the morning session on Friday. In the previous trading session, Aemetis stock closed at $2.44. The trading volume for the stock amounted to 5.23 million shares, which is lower
As of the last check Tuesday, Creative Realities Inc. (NASD: CREX) saw its shares rise 8.06% at $0.74 following news that it had received a takeover offer. Is anyone interested in buying CREX? The board of directors of Creative Realities (CREX) accepted an unsolicited bid
Energy Focus Inc. (NASDAQ: EFOI), a leading provider of energy-efficient lighting solutions, has seen a significant surge in its stock price in after-hours trading on Friday. According to the latest data, the company’s stock has advanced by 7.00% to reach a new level of $0.6418.
Following positive results from its research to treat malignancies, NovoCure Limited (NASDAQ: NVCR) shares jumped 67.57% to $118.19 on Thursday morning. Which NVCR study had fruitful outcomes? The LUNAR study showed a statistically significant and clinically significant increase in overall survival above conventional therapy alone,
Following the signing of a contract, LiqTech International Inc. (NASD: LIQT) was gaining on the charts yesterday, increasing 7.95% to trade at $0.3885 at the most recent check. Which contract did LIQT sign? For the purpose of commercializing a combination solution for acid purification, LiqTech
After the company announced an expansion of cooperation, shares of ProQR Therapeutics N.V. (Nasdaq: PRQR) were up 35.15% at $2.23 at the time of our last check in pre-market trading. What partnership will PRQR be extending? Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics
In Friday’s after-hours trading, Immuron Limited (NASDAQ: IMRN) shares increased 21.21% to $2.40 as the pharmaceutical company submitted an application for a new medication. Which document has IMRN filed? This month, Immuron (IMRN) said that it has applied for an investigational new drug (IND) designation
After-hours trading on Monday saw shares of Monopar Therapeutics Inc. (NASDAQ: MNPR) rise 8.78% to $2.23 following the release of encouraging clinical-trial data. What data has MNPR provided? Yesterday, Monopar Therapeutics (MNPR) published encouraging findings with MNPR-202 from its ongoing partnership with the National University
Upgrades and downgrades in analyst ratings can have a significant impact on stock prices. Even though these stocks may generate short-term earnings, analysts may downgrade them, culminating in negative results for investors. Analysts classify stocks into three subcategories: Analysts project a “BUY” recommendation for the
An analyst’s upgrades and downgrades can have a significant effect on a stock’s price. Short-term profits can come from stocks like these, but if analysts downgrade them or misjudge them, investment losses can also result. Analysts typically rate stocks based on three tiers: The stock
All rights reserved © 2024, Powered By Smart TechOne
